CN1255848A - 制备氟比洛芬锭剂的方法 - Google Patents
制备氟比洛芬锭剂的方法 Download PDFInfo
- Publication number
- CN1255848A CN1255848A CN98805123A CN98805123A CN1255848A CN 1255848 A CN1255848 A CN 1255848A CN 98805123 A CN98805123 A CN 98805123A CN 98805123 A CN98805123 A CN 98805123A CN 1255848 A CN1255848 A CN 1255848A
- Authority
- CN
- China
- Prior art keywords
- lozenge
- flurbiprofen
- forming composition
- mixture
- requirement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
制备药用锭剂制剂的方法,包括下列步骤:1)将氟比洛芬和填充剂的混合物用在极性溶剂中的粘合剂溶液制粒以形成颗粒;2)熔化锭剂、成形的组合物;3)将所述颗粒与熔化的锭剂－成形组合物混合;4)将所形成的混合物成形为每粒含治疗有效量的氟比洛芬的锭剂。
Description
本发明涉及制备含有氟比洛芬的药用组合物的改进方法，所述制剂为锭剂形式。氟比洛芬即[2-(2-氟代-4-联苯基)丙]酸是熟知的非甾体抗炎药，该药还具有镇痛和解热的活性。氟比洛芬分子以两种对映体形式存在，在此所用的术语“氟比洛芬”意思包含单独的对映体及其以任何比例(包括1∶1混合)的混合物，其在此指外消旋的氟比洛芬。氟比洛芬可以以药学上可接受的盐的形式或以衍生物如酯的形式存在，且此类盐或酯均包含在本文所用的术语氟比洛芬中。
氟比洛芬及其S(+)对映体被推荐用于治疗牙龈疾病。
EP 137668-A(Upjohn)描述氟比洛芬用于预防或抑制齿槽骨的吸收。
EP 486561-A(Sepracor)描述使用S(+)-氟比洛芬治疗牙周病并促进与此疾病有关的骨的再生长。可治疗的牙周病包括牙周炎、齿龈炎和牙周变性。
上述两份文件具体描述了齿龈病的治疗，但未涉及口腔的任何其它部分。
本发明提供的药用锭剂意在通过给予需要此种治疗的患者含有治疗有效量的氟比洛芬的药用锭剂组合物以用于治疗咽喉炎，所述药用锭剂组合物在口腔内释放氟比洛芬以便氟比洛芬传递至疼痛的咽喉表面。
该固体剂型为使患者吸收的锭剂。在此所用的术语“锭剂”意思包含其中该产品是通过冷却含有氟比洛芬的糖-基或糖醇基(如isomalt)的熔化物质形成的所有剂型。
已发现，当口服给予氟比洛芬以达到全身抗炎和/或镇痛效果时，其正常成人剂量的治疗有效量为5％-40％。因此，氟比洛芬可以以2.5-20mg(优选5-12.5mg)的量存在于药用组合物中。使用氟比洛芬的药学上可接受的盐时，所用的盐的量应该为，例如可提供所需氟比洛芬的量。适合的盐包括氟比洛芬的碱金属盐如钠盐或氨基酸盐如赖氨酸、精氨酸或甲基葡胺盐。
与其它非甾体抗炎剂类似，预料氟比洛芬停留在口腔时，会在口腔后部引起不愉快的灼烧感。这对接受治疗的患者来说，是明显不能接受的。本申请者令人吃惊地发现，当使用本发明提供的药用锭剂组合物治疗咽喉炎时，未出现不愉快的灼烧感，而是患者确实感觉咽喉疼痛症状得到解除。
根据本发明，提供生产药用锭剂制剂的方法，其包括下列步骤：1)将氟比洛芬和填充剂的混合物用在极性溶剂中的粘合剂溶液制粒以形成颗粒；2)熔化锭剂-成形的组合物；3)将所述颗粒与熔化的锭剂-成形组合物混合；4)使生成的混合物成形为每粒含治疗有效量的氟比洛芬的锭剂。
所述填充剂可以是碳酸钙、磷酸三钙、乳糖或微晶纤维素(如可在商品名Avicel下购得)。所述粘合剂可以是聚乙烯吡咯烷，所述极性溶剂可以是醇溶剂如工业用变性酒精(IMS)或异丙醇(IPA)。粘合剂的用量应足以确保所述颗粒坚固以便在贮存和转运过程中不致损坏。所述颗粒在与熔化的锭剂-成形组合物混合之前先干燥以除去极性溶剂。所述锭剂-成形组合物可以是糖基的或糖-醇基的组合物。如果所述锭剂-成形组合物是糖基的，它可以包括单糖(如蔗糖)或糖的混合物(如蔗糖和葡萄糖的混合物)。如果锭剂-成形组合物是糖-醇基的，它可以包括山梨醇、木糖醇、麦芽糖醇、麦芽糖醇糖浆、乳糖醇、甘露醇或其混合物，其可以为游离糖醇、其衍生物或其混合物的形式。一种优选的锭剂-成形组合物包括大约等摩尔的α-D-吡喃葡萄糖基-1，6-D-山梨醇和α-D-吡喃葡萄糖基(glucosopyranosyl)-1，1-D-甘露醇(isomalt)的混合物并任选与氢化葡萄糖糖浆如lycasin结合。所述锭剂-成形组合物最好在真空下加热至110℃-170℃的温度以除去水分，然后加入药用锭剂制剂的颗粒化的成分。水分含量优选低于2％，更优选低于1％。可使熔化的混合物通过各个模具，从中形成每个锭剂，或可将熔化的混合物吸成一个连续的圆柱体(mass)，从中形成单个的锭剂。然后冷却锭剂，经目测检查合格后进行适当的包装。一种适合的包装形式为由金属如铝箔密封的水-不渗透的塑料(如聚乙烯氯)的气泡眼包装。患者可挤压气泡眼以迫使锭剂压破包装并穿过密封的金属箔而取出锭剂。锭剂通常经患者吸入而释放出氟比洛芬。
除了上面所列的成分外，本发明提供的药用锭剂制剂可以含有其它组分如酸度调节剂、遮光剂、稳定剂、缓冲剂、矫味剂、甜味剂、着色剂和防腐剂。这些附加的成分可以在加入含氟比洛芬颗粒之前或之后溶解于熔化的锭剂-成形组合物中。在本发明的另一个实施方案中，这些附加的成分也可以掺入所述颗粒中。如果需要，可以对一种或多种附加成分进行包囊，以防止其它成分的相互作用，或者可以将一种或多种附加成分包括在对冷却的锭剂包衣的材料中。
本发明提供的药用锭剂制剂为可以经患者吸入并缓慢释放氟比洛芬的组合物。然后氟比洛芬穿过咽喉粘膜，其中一部分被吸收而提供局部释放。未吸收的氟比洛芬则经患者摄入并吸收进入血流。除了局部使用氟比洛芬于咽喉粘膜产生的缓解作用外，这样吸收的氟比洛芬可以全身起效而提供镇痛、抗炎和解热活性。本发明将通过下列实施例加以阐明，这些实施例仅作为举例的方式给出。
实施例1
制备每粒锭剂含有以mg表示的下列成分的药用锭剂制剂。
外消旋氟比洛芬 8.75
碳酸钙 7.5
聚乙烯吡咯烷 1.43
胶体二氧化硅(Aerosil) 0.036
硬脂酸镁 0.18
糖和液态葡萄糖1∶1混合物形成的固体 至2350
将氟比洛芬和碳酸钙混合2分钟，用聚乙烯吡咯烷的异丙醇溶液将所述混合物颗粒化。干燥该颗粒，加入胶体二氧化硅和硬脂酸镁并将生成的混合物混合5分钟。将糖和液态葡萄糖的混合物加热至140℃，真空降低熔化的糖锭剂基质的水分。然后将混合的颗粒混合物加入熔化的糖锭剂基质中。冷却生成的混合物并形成连续的圆柱体，从中制备单个的锭剂。
经上述步骤产生的颗粒很结实，在转运过程中足以避免损坏，在加工过程中显示出满意的流动性且不粘附在所接触的任何加工机械的金属表面上。
作为对比，一种类似的方法(其中氟比洛芬和碳酸钙不经制粒，而是在加入熔化的糖锭剂基质之前仅加以混合)得到较差的流动性的混合物并由此而产生所形成锭剂的氟比洛芬含量的不可接受的差异。其中氟比洛芬和碳酸钙在加入熔化的糖锭剂基质之前先用水制粒的方法得到的颗粒在其经受的加工条件下容易破碎且具有粘附于加工装置上的倾向。因此本发明提供含有氟比洛芬的药用锭剂制剂的改进的制备方法。
实施例2
以实施例1所述的类似方法制备还含有粉末状矫味剂的颗粒。制备其中矫味剂既不降解且不与氟比洛芬反应的满意的锭剂。
实施例3
制备每粒锭剂含有以mg表示的下列成分的药用锭剂制剂。
外消旋氟比洛芬 8.75
碳酸钙 7.5
聚乙烯吡咯烷 1.43
胶体二氧化硅(Aerosil) 0.036
硬脂酸镁 0.18
Isomalt 1885
Lycasin 440
矫味剂 见下面
将氟比洛芬和碳酸钙混合2分钟，用聚乙烯吡咯烷的异丙醇溶液将所述混合物颗粒化。干燥该颗粒，加入胶体二氧化硅和硬脂酸镁并将生成的混合物混合5分钟。通过将isomalt溶解于最少量的水中来制备熔化的锭剂基质。加入lycasin并于110℃-120℃加热该混合物。然后将该混合物真空加热至145℃以除去水分得到熔化的锭剂基质。然后将混合的颗粒和矫味剂(其为柚(3.75mg)、橙(1.65mg)和茴香(0.348mg)的混合物，其中括号中的量为存在于每粒锭剂中的每种矫味剂组分的量)加入熔化的锭剂基质中。冷却生成的混合物并形成连续的圆柱体，从中制备单个的锭剂。
经上述步骤产生的颗粒很结实，在转运过程中足以避免损坏，在加工过程中显示出满意的流动性且不粘附在所接触的任何加工机械的金属表面上。
Claims (9)
1.制备药用锭剂制剂的方法，其包括下列步骤：1)将氟比洛芬和填充剂的混合物用在极性溶剂中的粘合剂溶液制粒以形成颗粒；2)熔化锭剂-成形的组合物；3)将所述颗粒与熔化的锭剂-成形组合物混合；4)将所形成的混合物成形为每粒含治疗有效量的氟比洛芬的锭剂。
2.权利要求1的方法，其中所述填充剂为碳酸钙、磷酸三钙或微晶纤维素。
3.前述权利要求中任一项要求的方法，其中所述粘合剂为聚乙烯吡咯烷。
4.前述权利要求中任一项要求的方法，其中所述极性溶剂是工业用变性酒精或异丙醇。
5.前述权利要求中任一项要求的方法，其中所述锭剂-成形组合物包括一种或多种糖。
6.权利要求5要求的方法，其中所述锭剂-成形组合物包括蔗糖和葡萄糖的混合物。
7.权利要求1-4中任一项要求的方法，其中所述锭剂-成形组合物包括山梨醇、木糖醇、麦芽糖醇、麦芽糖醇糖浆、乳糖醇、甘露醇或其衍生物中的一种或多种。
8.权利要求7要求的方法，其中锭剂-成形组合物包括大约等摩尔的α-D-吡喃葡萄糖基-1，6-D-山梨醇和α-D-吡喃葡萄糖基-1，1-D-甘露醇的混合物。
9.权利要求8要求的方法，其中所述锭剂-成形组合物也包括氢化葡萄糖糖浆。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9710521.7A GB9710521D0 (en) | 1997-05-22 | 1997-05-22 | Process |
| GB9710521.7 | 1997-05-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1255848A true CN1255848A (zh) | 2000-06-07 |
| CN1154480C CN1154480C (zh) | 2004-06-23 |
Family
ID=10812840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988051230A Expired - Fee Related CN1154480C (zh) | 1997-05-22 | 1998-05-20 | 制备氟比洛芬锭剂的方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6194003B1 (zh) |
| EP (1) | EP0983059B1 (zh) |
| JP (1) | JP2001527567A (zh) |
| KR (1) | KR20010012739A (zh) |
| CN (1) | CN1154480C (zh) |
| AR (1) | AR015812A1 (zh) |
| AT (1) | ATE245021T1 (zh) |
| AU (1) | AU725760B2 (zh) |
| BG (1) | BG103881A (zh) |
| BR (1) | BR9809651A (zh) |
| CA (1) | CA2290830C (zh) |
| CZ (1) | CZ290816B6 (zh) |
| DE (1) | DE69816440T2 (zh) |
| DK (1) | DK0983059T3 (zh) |
| ES (1) | ES2202871T3 (zh) |
| GB (1) | GB9710521D0 (zh) |
| HU (1) | HU224954B1 (zh) |
| ID (1) | ID22949A (zh) |
| IL (1) | IL132999A0 (zh) |
| IN (1) | IN187837B (zh) |
| MY (1) | MY118410A (zh) |
| NO (1) | NO995681L (zh) |
| NZ (1) | NZ500664A (zh) |
| PL (1) | PL190947B1 (zh) |
| PT (1) | PT983059E (zh) |
| RU (1) | RU2203046C2 (zh) |
| SK (1) | SK283701B6 (zh) |
| TR (1) | TR199902725T2 (zh) |
| UA (1) | UA53714C2 (zh) |
| WO (1) | WO1998052539A1 (zh) |
| ZA (1) | ZA984260B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104780907A (zh) * | 2012-11-14 | 2015-07-15 | 皮埃尔法布雷医药公司 | 基于布洛芬钠二水合物的药用含片 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227045B1 (en) | 1999-12-09 | 2010-05-28 | Reckitt Benckiser Healthcare | Compressed tablet composition comprising a nsaid |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| JP4886107B2 (ja) * | 2000-10-13 | 2012-02-29 | サンスター株式会社 | 歯周病予防用口腔内溶解錠 |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| CA2532207A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| FR2865648B1 (fr) | 2004-02-03 | 2006-06-30 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| AU2005241023A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| EA013867B1 (ru) | 2005-02-03 | 2010-08-30 | Никомед Фарма Ас | Способ получения гранулята, содержащего карбонат кальция |
| GB2423710A (en) | 2005-03-01 | 2006-09-06 | Boots Healthcare Int Ltd | Lozenge production process |
| US20070042034A1 (en) * | 2005-07-22 | 2007-02-22 | Myriad Genetics, Incorporated | High drug load formulations and dosage forms |
| WO2007055887A1 (en) * | 2005-11-02 | 2007-05-18 | Teikoku Pharma Usa, Inc. | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same |
| US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
| AU2008279414A1 (en) * | 2007-07-23 | 2009-01-29 | Teikoku Pharma Usa, Inc. | Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
| US8569375B2 (en) * | 2008-08-22 | 2013-10-29 | Reckitt Benckiser Healthcare (Uk) Limited | Compositions |
| IT1397132B1 (it) | 2009-12-01 | 2013-01-04 | Alfa Wassermann Spa | Composizioni comprendenti antiinfiammatori non steroidei. |
| IT1406107B1 (it) * | 2010-12-13 | 2014-02-14 | Alfa Wassermann Spa | Composizioni solide comprendenti antiinfiammatori non steroidei, processi per la loro preparazione e loro uso. |
| LT2701681T (lt) | 2011-04-29 | 2016-12-12 | Moberg Pharma Ab | Farmacinės kompozicijos, apimančios vietinį anestetiką, tokį kaip bupivakainas, skirts vietiniam įvedimui į burną arba į gerklę |
| EP2609911A1 (en) * | 2011-12-29 | 2013-07-03 | Sanovel Ilac Sanayi ve Ticaret A.S. | A novel process for preparing orally disintegrating flurbiprofen formulations |
| JP6315741B2 (ja) * | 2015-08-18 | 2018-04-25 | 合同会社Ｐｈａｒｍａ Ｓｅｅｄｓ Ｃｒｅａｔｅ | ＮＳＡＩＤｓまたはヘパリン類含有口腔用組成物 |
| WO2020013781A2 (en) * | 2018-03-27 | 2020-01-16 | Pisak Mehmet Nevzat | Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4666716A (en) * | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| IT1243342B (it) | 1990-07-13 | 1994-06-10 | Farcon Ag | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
| US5302394A (en) | 1992-07-14 | 1994-04-12 | Mcneil-Ppc, Inc. | Dextromethorphan continuous lozenge manufacturing process |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| TW442287B (en) | 1995-06-13 | 2001-06-23 | American Home Produits Corp | Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac) |
| US5614207A (en) * | 1995-06-30 | 1997-03-25 | Mcneil-Ppc, Inc. | Dry mouth lozenge |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
-
1997
- 1997-05-22 GB GBGB9710521.7A patent/GB9710521D0/en active Pending
-
1998
- 1998-05-20 CN CNB988051230A patent/CN1154480C/zh not_active Expired - Fee Related
- 1998-05-20 JP JP54999298A patent/JP2001527567A/ja not_active Ceased
- 1998-05-20 PL PL336624A patent/PL190947B1/pl unknown
- 1998-05-20 BR BR9809651-6A patent/BR9809651A/pt not_active IP Right Cessation
- 1998-05-20 KR KR1019997010700A patent/KR20010012739A/ko not_active Application Discontinuation
- 1998-05-20 UA UA99127003A patent/UA53714C2/uk unknown
- 1998-05-20 DE DE69816440T patent/DE69816440T2/de not_active Expired - Lifetime
- 1998-05-20 IL IL13299998A patent/IL132999A0/xx not_active IP Right Cessation
- 1998-05-20 AT AT98929394T patent/ATE245021T1/de not_active IP Right Cessation
- 1998-05-20 HU HU0002121A patent/HU224954B1/hu not_active IP Right Cessation
- 1998-05-20 TR TR1999/02725T patent/TR199902725T2/xx unknown
- 1998-05-20 ES ES98929394T patent/ES2202871T3/es not_active Expired - Lifetime
- 1998-05-20 CZ CZ19994120A patent/CZ290816B6/cs not_active IP Right Cessation
- 1998-05-20 ZA ZA984260A patent/ZA984260B/xx unknown
- 1998-05-20 US US09/403,771 patent/US6194003B1/en not_active Expired - Lifetime
- 1998-05-20 SK SK1588-99A patent/SK283701B6/sk not_active IP Right Cessation
- 1998-05-20 EP EP98929394A patent/EP0983059B1/en not_active Expired - Lifetime
- 1998-05-20 AU AU79165/98A patent/AU725760B2/en not_active Ceased
- 1998-05-20 CA CA002290830A patent/CA2290830C/en not_active Expired - Fee Related
- 1998-05-20 ID IDW991324A patent/ID22949A/id unknown
- 1998-05-20 PT PT98929394T patent/PT983059E/pt unknown
- 1998-05-20 NZ NZ500664A patent/NZ500664A/xx not_active IP Right Cessation
- 1998-05-20 RU RU99126868/14A patent/RU2203046C2/ru not_active IP Right Cessation
- 1998-05-20 DK DK98929394T patent/DK0983059T3/da active
- 1998-05-20 WO PCT/EP1998/003167 patent/WO1998052539A1/en not_active Application Discontinuation
- 1998-05-21 IN IN1090MA1998 patent/IN187837B/en unknown
- 1998-05-21 AR ARP980102364A patent/AR015812A1/es not_active Application Discontinuation
- 1998-05-22 MY MYPI98002295A patent/MY118410A/en unknown
-
1999
- 1999-11-15 BG BG103881A patent/BG103881A/xx unknown
- 1999-11-19 NO NO995681A patent/NO995681L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104780907A (zh) * | 2012-11-14 | 2015-07-15 | 皮埃尔法布雷医药公司 | 基于布洛芬钠二水合物的药用含片 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1154480C (zh) | 制备氟比洛芬锭剂的方法 | |
| CA2238271C (en) | Pharmaceutical compositions comprising flurbiprofen | |
| US5922347A (en) | Pharmaceutical chewing gum containing acetylsalicylic acid | |
| KR101232114B1 (ko) | 용융 압출에 의해 제조된, 파라세타몰, ｎｓａｉｄ 및 당알콜 함유 과립 | |
| MX2007016072A (es) | Formulaciones de diclofenac y metodos para usarlas. | |
| WO1998052545A1 (en) | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat | |
| WO1998052540A1 (en) | Pharmaceutical compositions | |
| WO1994010994A1 (en) | Ibuprofen salt effervescent compositions | |
| MX2007009275A (es) | Procedimiento de produccion de pastillas que contienen maine, sus composiciones y su uso medicinal. | |
| MXPA99010548A (en) | Process for making flurbiprofen lozenges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RECKITT BENCKISER HEALTHCARE (UK) LIMITED Free format text: FORMER OWNER: THE BOOTS CO. PLC Effective date: 20070126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070126 Address after: Beck County Patentee after: Boots Healthcare Int Ltd. Address before: England, Nottingham, England Patentee before: The Boots Co. PLC |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040623 Termination date: 20170520 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |